Osteopore to Recruit First Patient for Jawbone Regeneration Trial After Research Governance Office Clearance

MT Newswires Live07-21

Osteopore (ASX:OSX) said that its clinical trial for jawbone regeneration, to be conducted in partnership with Princess Alexandra Hospital, secured clearance from the Research Governance Office, with the first patient expected to be recruited in four weeks, according to a Monday Australian bourse filing.

The single-arm feasibility study seeks to recruit at least 10 adult patients in Australia by 2028, and each patient will be assessed 36 months post-surgery.

The trial will study the safety and tolerability of the firm's polycaprolactone-tricalcium phosphate scaffold for maxillomandibular reconstruction, used in combination with a vascularized corticoperiosteal tissue transfer.

Its shares jumped over 15% on market close.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2553426389?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-21 14:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553426389","market":"nz","top_or_hot":-1,"title":"Osteopore to Recruit First Patient for Jawbone Regeneration Trial After Research Governance Office Clearance","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/OSX.AU\">Osteopore</a> (ASX:OSX) said that its clinical trial for jawbone regeneration, to be conducted in partnership with Princess Alexandra Hospital, secured clearance from the Research Governance Office, with the first patient expected to be recruited in four weeks, according to a Monday Australian bourse filing.</p><p>The single-arm feasibility study seeks to recruit at least 10 adult patients in Australia by 2028, and each patient will be assessed 36 months post-surgery.</p><p>The trial will study the safety and tolerability of the firm's polycaprolactone-tricalcium phosphate scaffold for maxillomandibular reconstruction, used in combination with a vascularized corticoperiosteal tissue transfer.</p><p>Its shares jumped over 15% on market close.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Osteopore to Recruit First Patient for Jawbone Regeneration Trial After Research Governance Office Clearance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOsteopore to Recruit First Patient for Jawbone Regeneration Trial After Research Governance Office Clearance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-07-21 14:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/OSX.AU\">Osteopore</a> (ASX:OSX) said that its clinical trial for jawbone regeneration, to be conducted in partnership with Princess Alexandra Hospital, secured clearance from the Research Governance Office, with the first patient expected to be recruited in four weeks, according to a Monday Australian bourse filing.</p><p>The single-arm feasibility study seeks to recruit at least 10 adult patients in Australia by 2028, and each patient will be assessed 36 months post-surgery.</p><p>The trial will study the safety and tolerability of the firm's polycaprolactone-tricalcium phosphate scaffold for maxillomandibular reconstruction, used in combination with a vascularized corticoperiosteal tissue transfer.</p><p>Its shares jumped over 15% on market close.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XKO.AU","symbol_name":"标普/澳交所 300指数","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2553426389","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553426389","pubTimestamp":1753079114,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Osteopore  said that its clinical trial for jawbone regeneration, to be conducted in partnership with Princess Alexandra Hospital, secured clearance from the Research Governance Office, with the first patient expected to be recruited in four weeks, according to a Monday Australian bourse filing.The single-arm feasibility study seeks to recruit at least 10 adult patients in Australia by 2028, and each patient will be assessed 36 months post-surgery.The trial will study the safety and tolerability of the firm's polycaprolactone-tricalcium phosphate scaffold for maxillomandibular reconstruction, used in combination with a vascularized corticoperiosteal tissue transfer.Its shares jumped over 15% on market close.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XKO.AU":"标普/澳交所 300指数","BK7126":"医疗保健用品","OSX.AU":"Osteopore","XJO.AU":"标普/澳交所 200指数","XAO.AU":"标普/澳交所 普通股指数"},"translate_title":"在研究管理办公室批准后，Osteopore将招募第一位患者进行颌骨再生试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OSX.AU":0.9,"XAO.AU":0.83,"XJO.AU":0.83,"XKO.AU":0.83},"content_text":"Osteopore (ASX:OSX) said that its clinical trial for jawbone regeneration, to be conducted in partnership with Princess Alexandra Hospital, secured clearance from the Research Governance Office, with the first patient expected to be recruited in four weeks, according to a Monday Australian bourse filing.The single-arm feasibility study seeks to recruit at least 10 adult patients in Australia by 2028, and each patient will be assessed 36 months post-surgery.The trial will study the safety and tolerability of the firm's polycaprolactone-tricalcium phosphate scaffold for maxillomandibular reconstruction, used in combination with a vascularized corticoperiosteal tissue transfer.Its shares jumped over 15% on market close.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2553426389","isCrawlerRequest":true}